Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5

Published:2020-09 Issue: Volume:18 Page:15-25
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Šaulytė Trakymienė Sonata¹,Economou Marina²,Kenet Gili³⁴⁵,Landorph Andrea⁶,Shen Chunduo⁶,Kearney Susan⁷

Affiliation:

1. Center for Pediatric Oncology and Hematology; Children's Hospital; Vilnius University Hospital Santaros Klinikos; Vilnius Lithuania

2. 1st Department of Pediatrics; Hippokration General Hospital; Aristotle University of Thessaloniki; Thessaloniki Greece

3. Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel

4. The Israeli National Hemophilia Center and Thrombosis Unit; Sheba Medical Center; Tel Hashomer Israel

5. The Amalia Biron Research Institute of Thrombosis and Hemostasis; Sheba Medical Center; Tel Hashomer Israel

6. Novo Nordisk A/S; Søborg Denmark

7. Center for Bleeding and Clotting Disorders; Children's Hospital Minnesota; Minneapolis MN USA

Funder

Novo Nordisk

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.15036/fullpdf

Reference11 articles.

1. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

2. Treatment Guidelines Working Group on Behalf of The World Federation Of Haemophilia. Guidelines for the management of hemophilia;Srivastava;Haemophilia,2013

3. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A;Tiede;J Thromb Haemost,2013

4. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A;Meunier;Thromb Haemost,2017

5. Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII;Kearney;Patient Prefer Adherence,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results;Journal of Thrombosis and Haemostasis;2023-11

2. Cases of less‐than‐expected FVIII activity in previously treated patients during post‐marketing surveillance of N8‐GP;Haemophilia;2023-09-20

3. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A;Blood Advances;2023-02-21

4. Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports;BMC Medicine;2022-05-20

5. Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study;Research and Practice in Thrombosis and Haemostasis;2022-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3